RecruitingNot ApplicableNCT06604325

Prophylactic Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery.

Prophylactic Role Of Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery : A Prospective Study.


Sponsor

Aligarh Muslim University

Enrollment

300 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality. Globally, it is responsible for 25% of all pregnancy-related deaths. PPH is unpredictable and may occur in the absence of risk factors. Tranexamic acid is an antifibrinolytic proven to reduce blood loss and transfusion requirements for various surgeries. This study aims to explore the effectiveness of tranexamic acid as an adjunct to other uterotonics before the Caesarian Section.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Inclusion Criteria2

  • The women undergoing cesarean delivery (both elective and emergency) during the study period.
  • Willing to participate in the study after understanding the concept.

Exclusion Criteria3

  • Critically ill patient.
  • Not willing to give consent to participate in the study
  • Cases diagnosed with a ruptured uterus or undergoing caesarian hysterectomy during operation.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTranexamic acid injection

All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.

DRUGPlacebo

All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.


Locations(1)

ASJSATDS Medical College

Fatehpur, Uttar Pradesh, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06604325


Related Trials